PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

GlaxoSmithKline places its shingles vaccine ... Another company developing a vaccine for herpes zoster is US biotech Curevo Vaccine, whose adjuvanted subunit vaccine CRV-101 is in early-stage ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody ...

Shingrix [Herpes Zoster vaccine (recombinant, AS01 B ix adjuvanted)] is a non-live, recombinant subunit vaccine indicated for the prevention of shingles (herpes zoster) and, in some markets, for ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

The Advisory Committee on Immunization Practices (ACIP) recommends a single dose of zoster vaccine for immunocompetent adults 60 years of age and older, based on the results of this study ...